<DOC>
	<DOCNO>NCT00002141</DOCNO>
	<brief_summary>To assess safety single oral dos 1592U89 ( abacavir succinate , ABC ) administer HIV-positive individual . To determine pharmacokinetics 1592U89 single oral dos . To determine effect food bioavailability 1592U89 .</brief_summary>
	<brief_title>A Phase I Trial Evaluate Safety Pharmacokinetics 1592U89</brief_title>
	<detailed_description>Patients randomize double-blinded manner , 12 patient enter treatment arm 6 patient enter control arm . Patients treatment arm receive 6 single escalate dos 1592U89 separate least 6-day washout period . Patients control arm receive 6 single oral dos placebo least 6 day apart . The second third dos 1592U89 equivalent . During dos , investigator study effect food pharmacokinetics 1592U89 give half patient second dose standardize , high-fat breakfast give half dose fast state . During third dose , patient cross patient receive second dose meal receive fast state , vice versa . Following sixth dose , investigator break blind . Patients receive 1592U89 take seventh dose solution form return follow-up least 7 day later ; patient receive placebo receive treatment follow-up . Serial blood urine sample collect administration 1592U89 ( placebo ) determination plasma urine concentration 1592U89 , investigator monitor patient closely adverse event abnormal laboratory test finding .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection , document ELISA/Western blot detection HIV antibody , positive p24 antigen assay , positive viral culture , accept technique . Written inform consent parent legal guardian age 18 . Exclusion Criteria Coexisting Condition : Excluded : Debilitating disease , result HIV associate therapy , , opinion investigator , might prevent patient complete 6week dosing period . Malabsorption syndrome gastrointestinal dysfunction might interfere drug absorption . Concurrent Medication : Excluded : Prescription overthecounter medication withhold 48 hour prior dose 6 dose period . ( Note : Antiretrovirals must withhold 24 hour prior dose day dose . ) Other investigational treatment ( treatment available Treatment IND expand access mechanism evaluate individually consultation sponsor ) . Alcoholic beverage within 48 hour dose day dose . Coffee , tea , xanthinecontaining beverage food day dose . Patients follow symptoms condition exclude : History hepatitis , pancreatitis , cardiomyopathy within last 5 year . Risk Behavior : Excluded : Current alcohol illicit drug use might interfere patient 's ability comply dose schedule protocol evaluation , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 1994</verification_date>
	<keyword>Biological Availability</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Food-Drug Interactions</keyword>
	<keyword>abacavir</keyword>
</DOC>